# Phosphodiesterase Type-5 Inhibitor Therapy in Sickle Cell People With Pulmonary Hypertension

> **NCT03572036** · — · COMPLETED · sponsor: **National Heart, Lung, and Blood Institute (NHLBI)** · enrollment: 38 (actual)

## Conditions studied

- Pulmonary Hypertension
- Sickle Cell Disease

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT03572036
- **Lead sponsor:** National Heart, Lung, and Blood Institute (NHLBI)
- **Sponsor class:** NIH
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2018-06-20
- **Primary completion:** 2021-04-16
- **Final completion:** 2021-04-16
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2021-04-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03572036

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03572036, "Phosphodiesterase Type-5 Inhibitor Therapy in Sickle Cell People With Pulmonary Hypertension". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT03572036. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*